Jim Simons's position in Exelixis is currently worth $591M. That's 0.75% of their equity portfolio (15th largest holding). The investor owns 5.87% of the outstanding Exelixis stock. The first Exelixis trade was made in Q2 2014. Since then Jim Simons bought shares 24 more times and sold shares on eighteen occasions. The stake costed the investor $329M, netting the investor a gain of 80% so far.
Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obes...